The NMPA has granted breakthrough-therapy-designated drug for B7-H4-targeted antibody-drug conjugate HS-20089

CAR-T Digest - August 2020

1 May 2025: The NMPA has granted breakthrough-therapy-designated drug for B7-H4-targeted antibody-drug conjugate HS-20089

Hansoh Pharmaceuticals B7-H4-targeted ADC, HS-20089, has been granted BTD by China’s National Medical Products Administration (NMPA)
The designation supports the development of HS-20089 for patients with platinum-resistant recurrent epithelial Ovarian, Fallopian tube, or primary Peritoneal cancer
The NMPA’s decision highlights the therapy’s potential for significant clinical improvement over existing treatments
HS-20089 is a self-developed ADC by Hansoh, aimed at addressing high unmet medical needs in hard-to-treat gynecologic cancers
This regulatory milestone accelerates HS-20089’s development path and underscores Hansoh’s growing capabilities in innovative oncology therapeutics